Home
/ Abivax
/ Competitors

Abivax Competitors and Similar CompaniesClear all

Abivax's competitors and similar companies include APEIRON Biologics, UCB, Cipla and Mankind Pharma.

	Abivax Abivax is a biotech company that mobilizes the body’s natural immune system to treat patients suffering from inflammatory diseases, infectious diseases, and cancer.	APEIRON Biologics APEIRON Biologics is a biotech company focused on the discovery and development of cancer immunotherapies.	UCB UCB is a company that provides biopharmaceutical research and development solutions for neurological and immunological conditions.	Cipla Cipla is a pharmaceutical company focused on the development, manufacturing, and distribution of medications and healthcare products.	Mankind Pharma Mankind Pharma is a pharmaceutical company developing, commercializing, and delivering medicines.
Founding Date	Founding Date 2013	Founding Date 2005	Founding Date 1928	Founding Date 1935	Founding Date 1995
Type	Type Public	Type Private	Type Public	Type Public	Type Private
Tags	Tags Healthcare biotech drug development pharma	Tags Healthcare biotech clinical research drug development medical records oncology therapy	Tags Healthcare biotech drug development pharma	Tags Healthcare biotech drug development pharma	Tags Healthcare biotech drug development pharma
Locations	Locations Paris, FR HQ Montpellier, FR Montpellier, FR Waltham, US	Locations Wien, AT HQ	Locations Brussels, BE HQ Melbourne, AU Vienna, AT Braine L'alleud, BE Braine L'alleud, BE Leuven, BE São Paulo, BR see more	Locations Mumbai, IN HQ Melbourne, AU Antwerpen, BE São Paulo, BR São Paulo, BR Unterhaching, DE Nairobi, KE see more	Locations New Delhi, IN HQ
Employees	Employees 69	Employees 5	Employees 9,052	Employees 27,764	Employees 16,2532% increase
Valuation ($)	Valuation ($) 672.6 m	Valuation ($) N/A	Valuation ($) 34.3 b	Valuation ($) N/A	Valuation ($) N/A
Financial
Revenue (est.)	Revenue (est.) N/A	Revenue (est.) N/A	Revenue (est.) €7.4b (FY, 2025)	Revenue (est.) ₹277.1b (FY, 2026)	Revenue (est.) N/A
Cost of goods	Cost of goods N/A	Cost of goods N/A	Cost of goods €1.4b (FY, 2025)	Cost of goods ₹95.5b (FY, 2026)	Cost of goods N/A
Gross profit	Gross profit €4.6m (FY, 2025)	Gross profit N/A	Gross profit €7.2b (FY, 2025)	Gross profit ₹195b (FY, 2026)	Gross profit N/A
Net income	Net income (€336.1m) (FY, 2025)	Net income N/A	Net income €1.6b (FY, 2025)	Net income ₹38.7b (FY, 2026)	Net income N/A
Funding
Total funding raised	Total funding raised $ 13.5m	Total funding raised N/A	Total funding raised N/A	Total funding raised N/A	Total funding raised $ 239m